Results 81 to 90 of about 121,794,009 (205)

Botulinum toxin: a new differential diagnosis for a lytic bone lesion

Journal of Medical Case Reports
Background Botulinum toxin, produced by the Gram-positive anaerobe Clostridium botulinum, is composed of seven antigenic subtypes (A, B, C, D, E, F, and G). Currently, only Botulinum toxin type A, commonly referred to as “Botox,” is approved for clinical
Yael Lefkovits, Lara Lipton
doaj   +1 more source

The Hidden Burden of Hemifacial Spasm: A Systematic Review of Non‐Motor Symptoms

Movement Disorders Clinical Practice, Volume 13, Issue 9, Page 2059-2071, September 2026.
Abstract Background Hemifacial spasm (HFS) is a chronic neurological disorder characterized by involuntary contractions of facial muscles. Traditionally regarded as a motor condition, HFS encompasses a spectrum of non‐motor symptoms that are often overlooked but significantly affect patients’ quality of life.
Miriam Carvalho Soares, Jacy Bezerra Parmera, Pedro Augusto Sampaio Rocha‐Filho   +2 more
wiley   +1 more source

Botulinum toxin a in the treatment of blepharospasm - A 10-year experience [PDF]

, 2005
To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clinicas ...
Goncalves, LR, Chien, HF, Silveira-Moriyama, L, Lilian R. Gonçalves, Laura Silveira-Moriyama, Barbosa, ER, Egberto R. Barbosa, Hsin Fen Chien   +7 more
core   +1 more source

European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0–18 years

Journal of Pediatric Gastroenterology and Nutrition, Volume 83, Issue 2, Page 335-366, August 2026.
Abstract Objectives Functional constipation (FC) is common in childhood, significantly impacting quality of life. Since the 2014 international guideline, new evidence has been published, and methods on making guidelines have developed. This treatment guideline for FC in children aged 0–18 years is a collaborative effort of the European and North ...
Morris Gordon, Anna de Geus, Mary Boruta, Marcin Banasiuk, Marc Benninga, Osvaldo Borrelli, Anil Darbari, Dawn Dore‐Stites, Michelle Gould, Juliette Hawa, Kirsten Jones, Alexandra Kilgore, Hayat Mousa, Samuel Nurko, Nikhil Thapar, Julie Khlevner, Vasiliki Sinopoulou, Merit Tabbers   +17 more
wiley   +1 more source

Over 25 Years of Pediatric Botulinum Toxin Treatments: What Have We Learned from Injection Techniques, Doses, Dilutions, and Recovery of Repeated Injections?

Toxins, 2020
Botulinum toxin type A (BTXA) has been used for over 25 years in the management of pediatric lower and upper limb hypertonia, with the first reports in 1993.
Heli Sätilä
doaj   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, Volume 13, Issue 8, Page 1848-1860, August 2026.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Structural Basis for BABIM Inhibition of Botulinum Neurotoxin Type B Protease

, 2016
Structural Basis for BABIM Inhibition of Botulinum Neurotoxin Type B ...
Michael A. Hanson (2213152), Daniel H. Rich (1972099), Raymond C. Stevens (270962), Chanokporn Sukonpan (2984046), Thorsten K. Oost (2503873)   +4 more
core   +1 more source

Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks [PDF]

, 2010
Objective improvement following intradetrusor injections of botulinum neurotoxin type A (BoNTA) is well documented. Although patient-related outcome measures are highly recommended for monitoring overactive bladder symptoms, no study before has dealt ...
Panicker, Jalesh, Khan, Shahid, Kessler, Thomas M, Dasgupta, Prokar, Fowler, Clare J, Elneil, Sohier, Roosen, Alexander, Gonzales, Gwen, Jalesh Panicker, Thomas M. Kessler, Clare J. Fowler, Sohier Elneil, Shahid Khan, Prokar Dasgupta, Alexander Roosen, Gwen Gonzales   +15 more
core   +1 more source

MDSGene Systematic Review of Common Forms of Dominant Hereditary Spastic Paraplegia: Novel Insights

Movement Disorders Clinical Practice, Volume 13, Issue 8, Page 1804-1814, August 2026.
Abstract Background Hereditary spastic paraplegia (HSP) is a neurodegenerative disorder characterized by progressive spasticity and lower limb weakness. The most common forms of autosomal dominant HSP are caused by pathogenic variants in SPAST (SPG4 or HSP‐SPAST), ATL1 (SPG3A or HSP‐ATL1), and REEP1 (SPG31 or HSP‐REEP1).
Ce Kang, Rajasumi Rajalingam, Zachary Walls, Jana Huang, Christine Sun, Laura I. Rudaks, Dennis Yeow, Ashar Rasheed, Jenny W. Zhang, Moath Hamed, Marianthi Breza, Susen Schaake, Chetan Vekhande, Jason Massa, Robyn E. Massa, Aakash Shetty, Carolyn M. Sue, Franca Cambi, Oksana Suchowersky, Franca Vulinovic, Sonja Petkovic, Christine Klein, Katja Lohmann, Connie Marras, Kishore R. Kumar   +24 more
wiley   +1 more source

Neurologic uses of botulinum neurotoxin type A

, 2007
John P Ney, Kevin R JosephMadigan Army Medical Center, Neurology Service, Tacoma, WA, USAAbstract: This article reviews the current and most neurologic uses of botulinum neurotoxin type A (BoNT-A), beginning with relevant historical data, neurochemical ...
Kevin R Joseph, John P Ney
core